Clinical rating scales for dystonia;Les échelles cliniques de la dystonie

Revue Neurologique

Volumn 159, Issue 10 I, 2003, Pages 906-915

  Vercueil, L ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; BLEPHAROSPASM; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC VALUE; DYSTONIA; GENETIC DISORDER; GLOBAL DYSTONIA SCALE; INTERMETHOD COMPARISON; PHENOMENOLOGY; RATING SCALE; RELIABILITY; REVIEW; UNIFIED DYSTONIA RATING SCALE; VALIDATION PROCESS;

DYSTONIA; DYSTONIC DISORDERS; HUMANS;

EID: 0141892584     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. BAIN PG, FINLEY LJ, ATCHISON P, et al. (1993). Assessing tremor severity. J Neurol Neurosurg Psychiatry, 56: 868-873.
2. BEREZNAI B, STEUDE U, SEELOS K, et al. (2002). Chronic high-frequency globus pallidus internus stimulation in different types of dystonia: a clinical, video, and MRI report of six patients presenting with segmental, cervical, and generalized dystonia. Mov Disord, 17: 138-44.
3. BLACKIE JD, LEES AJ. (1990). Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry, 53: 640-3.
4. BLITZER A, BRIN MF, STEWART CF. (1998). Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope, 108: 1435-41.
5. BRANS JW, LINDEBOOM R, SNOEK JW, et al. (1996). Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology, 46: 1066-72.
6. BRASHEAR A, TRUONG D, CHARLES D, et al. (1998). A randomized, double-blind, placebo-controlled study of intramuscular botox for the treatment of cervical dystonia (CD). Mov Disord, 13: 276.
7. BRASHEAR A, LEW MF, DYKSTRA DD, et al. (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology, 53: 1439-46.
8. BRESSMAN SB. (2000). Dystonia update. Clin Neuropharmacol, 23: 239-251.
9. BRIN MF, LEW MF, AOLER CH, et al. (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology, 53: 1431-8.
10. BUCHMAN AS, COMELLA CL, STEBBINS GT, et al. (1993). Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol, 16: 205-210.
11. BURKE RE, FAHN S, MARSDEN CD, et al. (1985). Validity and reliability of a rating scale for the primary torsion dystonias. Neurology, 35: 73-7.
12. BYL NN, MCKENZIE A. (2000). Treatment effectiveness for patients with a history of repetitive hand use and focal hand dystonia: a planned, prospective follow-up study. J Hand Ther, 13: 289-301.
13. CHAN J, BRIN MF, FAHN S. (1991). Idiopathic cervical dystonia: clinical characteristics. Mov Disord, 6: 119-126.
14. COLES R, HALETT M, COHEN LG. (1995). Double blind trial of botulinum todin for treatment of focal hand dystonia. Mov Disord, 10: 466-71.
15. COMELLA CL, BUCHMAN AS, TANNER CM, et al. (1992a). Botulinum toxin injections for spasmodic torticollis: increased magnitude of venefit with electromyographic assistance. Neurology, 42: 878-882.
16. COMELLA CL, TANNER CM, DEFOOR-HILL L, et al. (1992b). Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiological findings. Neurology, 42: 1307-1310.
17. COMELLA CL, STEBBINS GT, GOETZ CG, et al. (1997). Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord, 12: 570-5.
18. COMELLA CL, LEURGANS S, WUU J, et al. (2003). Rating scales for dystonia: A multicenter assessment. Mov Disord, 18: 303-12.
19. CONSKY ES, LANG AE. (1994). Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, Eds. Therapy with botulinum toxin. New York, NY: Marcel Dekker: pp. 211-237.
20. COOPER IS (1969). Involuntary movement disorders. Harper & Row, New York.
21. COUBES P, ROUBERTIE A, VAYSSIERE N, et al. (2000). Treatment of DYT1-generalised dystonia by stimulation of internal globus pallidus. Lancet, 355: 2220-1.
22. CUBO E, GRACIES JM, BENABOU R, et al. (2001). Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol, 58: 1379-82.
23. DEFAZIO G, LEPORE V, ABBRUZZESE G, et al. (1994). Reliability among neurologists in the severity assessment of blepharospasm and oromandibular dystonia: a multicenter study. Mov Disord, 9: 616-21.
24. FAHN S. (1988). Concept and classification of Dystonia. Adv Neurol, 50: 1-8.
25. FAHN S. (1989). Assessment of the primary dystonia. In: Munsat T ed. Quantification of neurologic deficit. London: Butterworths: pp. 241-270.
26. FORD B, LOUIS ED, GREENE P, et al. (1998). Outcome of selective ramisectomy for botulinum toxin resistant torticollis J Neurol Neurosurg Psychiatry, 65: 472-8.
27. GERLACH J, KORSGAARD S, CLEMMESEN P, et al. (1993). The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand, 87: 244-52.
28. GOETZ C, STEBBINS GT, SHALE HM, et al. (1994). Utility of an objective dyskinesia rating scale for Parkinsonís disease: inter- and intrarater reliability assessment. Mov Disord, 9: 390-394.
29. GOETZ C. (2001). L'histoire des dystonies. Rev Neurol (Paris), 157: 446-449.
30. GREENE P, KANG U, FAHN S, et al. (1990). Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology, 40: 1213-18.
31. HAGELL P, WIDNER H. (1999). Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord, 14: 448-55.
32. HUNTINGTON STUDY GROUP. (1996). Unified Huntingtonís Disease Rating Scale: reliability and consistency. Mov Disord, 11: 136-142.
33. JAHANSHAHI M. (2000). Factors that ameliorate or aggravate spasmodic torticollis. J Neurol Neurosurg Psychiatry, 68: 227-9.
34. JANKOVIC J, ORMAN J. (1987). Botulinum A toxin for cranial-cervical dystonia: a double-blind placebo controlled study. Neurology, 37: 616-623.
35. JANKOVIC J, SCHWARTZ K, DONOVAN DT. (1990). Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spams. J Neurol Neurosurg Psychiatry, 53: 633-639.
36. JANKOVIC J, SCHWARTZ KS. (1993). Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg (Am), 18: 883-7.
37. JEDYNAK CP, BONNET AM, AGID Y. (1991). Tremor and idiopathic dystonia. Mov Disord, 6: 230-236.
38. JEDYNAK CP, POLLAK P. (2000). Dystonie et co-contraction. Mouvements, 1: 13-16.
39. KARP BI, GOLDSTEIN SR, CHEN R, et al. (1999). An open trial of clozapine for dystonia. Mov Disord, 14: 652-7.
40. KOLLER W, VETERE-OVERFIELD B, GRAY C, et al. (1990). Failure of fixed-dose, fixed muscle injection of botulinum toxin in torticollis. Clin Neuropharmacol, 13: 355-8.
41. KOMAN LA, BRASHEAR A, ROSENFELD S, et al. (2001). Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics, 108: 1062-71.
42. KRAUSS JK, TOUPS EG, JANKOVIC J, et al. (1997). Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry, 63: 642-8.
43. KRAUSS JK, LOHER TJ, POHLE T, et al. (2002). Pallidal deep brain stimulation in patients with cervical dystonia and severe cervical dyskinesias with cervical myelopathy. J Neurol Neurosurg Psychiatry, 72: 249-56.
44. KRYSTKOWIAK P, DEFEBVRE L. (2002). La Rush Dyskinesias Scale ou échelle de Goetz. Rev Neurol (Paris), 158: 622-624.
45. LAUBIS-HERRMANN U, FRIES K, TOPKA H. (2002). Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study. Eur Neurol, 47: 214-21.
46. LEW MF, ADORNATO BT, DUANE DD, et al. (1997). Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia Neurology, 49: 701-7.
47. LINDEBOOM R, DE HAAN RJ, ARAMIDEH M, et al. (1996). Treatment outcomes in cervical dystonia: a clinimetric study. Mov Disord, 11: 371-376.
48. LOONEN AJ, DOORSCHOT CH, VAN HEMERT DA, et al. (2000). The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity. Int J Neuropsychopharmacol, 3: 285-296.
49. LOONEN AJ, DOORSCHOT CH, VAN HEMERT DA, et al. (2001). The schedule for the assessment of drug-induced movement disorders (SADIMoD): inter-rater reliability and construct validity. Int J Neuropsychopharmacol, 4: 347-60.
50. LOUIS ED, LEE P, QUINN L, et al. (1999). Dystonia in Huntington's disease: prevalence and clinical characteristics Mov Disord, 4: 95-101.
51. LOUIS ED, ANDERSON KE, MOSKOWITZ C, et al. (2000). Dystonia-predominant adult-onset Huntington disease: association between motor phenotype and age of onset in adults. Arch Neurol, 57: 1326-30.
52. MAZARS G, MERIENNE L, GOTUSSO C, et al. (1970). Les dyskinésies du membre supérieur associées aux dyskinésies d'orientation céphalique. Étude portant sur 45 cas, présentation de films. Rev Neurol (Paris), 122: 275-7.
53. MUNCHAU A, PALMER JD, DRESSLER D, et al. (2001). Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain, 124: 769-83.
54. NUTT JG, NYGAARD TG. (2001). Response to levodopa treatment in dopa-responsive dystonia. Arch Neurol, 58: 905-10.
55. OIBRIEN C, BRASHEAR A, CULLIS P, et al. (2001). Cervical dystonia severity scale reliability study. Mov Disord, 16: 1086-1090.
56. ODERGREN T, TOLLBACK A, BORG J. (1994). Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation Scand J Rehabil Med, 26: 191-5.
57. ONDO WG, DESALOMS JM, JANKOVIC J, et al. (1998). Pallidotomy for generalized dystonia. Mov Disord, 13: 693-8.
58. POEWE W, DEUSCHL G, NEBE A, et al. (1998). What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry, 64: 13-7.
59. PRIORI A, PESENTI A, CAPPELLARI A, et al. (2001). Limb immobilization for the treatment of focal occupational dystonia. Neurology, 14; 57:3 405-9.
60. RONDOT P, MARCHAND MP, DELLATOLAS G. (1991). Spasmodic torticollis- review of 220 patients. Can J Neurol Sci, 18: 143-151.
61. TAN EK, JANKOVIC J. (2000). Tardive and idiopathic oromandibular dysotina: a clinical comparison. J Neurol Neurosurg Psychiatry, 68: 186-1990.
62. TARSY D. (1997). Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord, 12: 100-2.
63. TRANCHANT C (2000). Les dystonies focales. Aspects cliniques, étiologiques, et thérapeutiques. Rev Neurol (Paris), 156: 1087-1094.
64. TSUI JKC, EISEN A, STOESSL AJ, CALNE S, et al. (1986). Double-blind study of botulinum toxin in spasmodic torticollis. Lancet, 2: 245-7.
65. TUBIANA R, CHAMAGNE P. (1993). Les affections professionnelles du member supérieur chez le musician. Bull Acad Natl Med, 177: 203-216.
66. VAN HARTEN PN, KAMPUIS DJ, MATROOS GE (1996a). Use of clozapine in tardive dystonia. Prog Neuropsychopharmacol Biol Psychiatry, 20: 263-74.
67. VAN HARTEN PN, MATROOS GE, HOEK HW, et al. (1996b). The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res, 19: 195-203.
68. VAYSSIERE N, HEMM S, ZANCA M, et al. (2000). Magnetic resonance imaging stereotactic target localization for deep brain stimulation in dystonic children. J Neurosurg, 93: 784-90.
69. WALKER RH, DANISI FO, SWOPE DM, et al. (2000). Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord, 15: 1242-7.
70. WISSEL J, KABUS C, WENZEL R, et al. (1996). Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry, 61: 172-5.